Item 7.01. Regulation FD Disclosure | ||||||||
| Item 8.01. Other Information | ||||||||
| Item 9.01. Financial Statements and Exhibits | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| Press Release | ||||||||
Table of Contents
| Item 7.01. | Regulation FD Disclosure |
Repros Therapeutics Inc. (the “Company”) announced today that its management will hold a
conference call to provide an update on the Company’s current status and to answer questions at
12:00 noon Central Time on August 21, 2008. Domestic callers may dial: 866-559-7315 and
International callers may dial: 404-665-9488. The Conference ID is: 60828548.
| Item 8.01. | Other Information |
The Company today announced that based on the efficacy demonstrated by Proellex® in the
interim assessment of the Company’s Phase II endometriosis study, there are sufficient patients
currently enrolled to provide for adequate power calculations for the Phase III endometriosis
trials.
A copy of the Company’s press release is attached hereto as Exhibit 99.1. The press release
is incorporated by reference herein and the foregoing description of the press release is qualified
in its entirety by reference to the attached exhibit.
| Item 9.01. | Financial Statements and Exhibits |
d. Exhibits
| Exhibit | ||||
| Number | Description | |||
| 99.1 | Press Release dated August 18, 2008 |
|||